{"id":578310,"date":"2021-12-07T18:32:01","date_gmt":"2021-12-07T18:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=578310"},"modified":"2021-12-07T18:32:01","modified_gmt":"2021-12-07T18:32:01","slug":"dystrophic-epidermolysis-bullosa-epidemiology-analysis-in-the-7mm-during-the-study-period-201830-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dystrophic-epidermolysis-bullosa-epidemiology-analysis-in-the-7mm-during-the-study-period-201830-by-delveinsight_578310.html","title":{"rendered":"Dystrophic Epidermolysis Bullosa epidemiology analysis in the 7MM during the study period (2018-30) by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1638881224.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dystrophic Epidermolysis Bullosa epidemiology analysis in the 7MM during the study period (2018-30) by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1638881224.png\" alt=\"Dystrophic Epidermolysis Bullosa epidemiology analysis in the 7MM during the study period (2018-30) by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Dystrophic Epidermolysis Bullosa Epidemiology Forecast<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s Dystrophic Epidermolysis Bullosa epidemiology forecast report provides a comprehensive understanding of Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology, and Dystrophic Epidermolysis Bullosa trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/f70426c6e072f493350e0bd70494890e.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-epidemiology-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Dystrophic Epidermolysis Bullosa epidemiology forecast report<\/a> <\/strong>provides a comprehensive understanding of Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology, and Dystrophic Epidermolysis Bullosa trends in the 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Takeaways from the Dystrophic Epidermolysis Bullosa Epidemiology Forecast Report<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight&rsquo;s Dystrophic Epidermolysis Bullosa epidemiology insights, the total diagnosed prevalent cases were <strong>40,238<\/strong> in the 7MM in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the estimates, out of all the DEB diagnosed prevalent cases in the US, <strong>52.5%<\/strong> of cases were of Dominant Dystrophic Epidermolysis Bullosa (DDEB).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Among the EU5, <strong>Germany<\/strong> had the highest DEB diagnosed prevalent cases while <strong>France<\/strong> had the lowest in 200.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In Japan, the DEB diagnosed prevalent cases was over <strong>1 thousand<\/strong> in 2020.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">To learn more about the symptoms, diagnosis, and treatment, request for sample @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dystrophic-epidermolysis-bullosa-epidemiology-forecast\">Dystrophic Epidermolysis Bullosa Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Dystrophic Epidermolysis Bullosa: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Dystrophic Epidermolysis Bullosa (DEB) is one of the most common types of EB. Mutations in the COL7A1 gene cause it, and it can be inherited in an autosomal dominant or autosomal recessive manner. Mutations in COL7A1, which encodes type VII collagen, a major component of anchoring fibrils, cause all DEB subtypes.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Dystrophic Epidermolysis Bullosa Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Dystrophic Epidermolysis Bullosa report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Epidermolysis Bullosa Total Diagnosed Prevalent Population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dystrophic Epidermolysis Bullosa Total Diagnosed Prevalent Population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dystrophic Epidermolysis Bullosa Subtype-Specific Diagnosed Prevalent Population<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a detailed analysis of epidemiology segmentation @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dystrophic-epidermolysis-bullosa-epidemiology-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Dystrophic Epidermolysis Bullosa Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"77\" \/>\n<col width=\"547\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Dystrophic Epidermolysis Bullosa (DEB) Epidemiology Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Dystrophic Epidermolysis Bullosa (DEB): Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Country Wise Epidemiology of Dystrophic Epidermolysis Bullosa<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epidermolysis-bullosa-eb-epidemiology-forecast?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Epidermolysis Bullosa Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>&#8220;DelveInsight&rsquo;s &lsquo;Epidermolysis Bullosa (EB)-Epidemiology Forecast&ndash;2030&rsquo;<\/strong> report delivers an in-depth understanding of the EB, historical and forecasted epidemiology as well as the EB trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dystrophic-epidermolysis-bullosa-epidemiology-analysis-in-the-7mm-during-the-study-period-201830-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dystrophic-epidermolysis-bullosa-epidemiology-analysis-in-the-7mm-during-the-study-period-201830-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dystrophic Epidermolysis Bullosa Epidemiology Forecast DelveInsight\u2019s Dystrophic Epidermolysis Bullosa epidemiology forecast report provides a comprehensive understanding of Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology, and Dystrophic Epidermolysis Bullosa trends in the 7MM. DelveInsight&rsquo;s Dystrophic Epidermolysis Bullosa epidemiology forecast report provides &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dystrophic-epidermolysis-bullosa-epidemiology-analysis-in-the-7mm-during-the-study-period-201830-by-delveinsight_578310.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-578310","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=578310"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/578310\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=578310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=578310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=578310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}